Background: HLA-DRB1*1501 (DR15) and other HLA class II alleles increase the risk of developing multiple sclerosis (MS). However, the contribution of genetic heterogeneity to the clinical course of MS remains controversial. We examined the influence of DR15 and other common DRB1 alleles (DRB1*01 (DR1), DRB1*03 (DR3) and DRB1*04 (DR4) on MS severity in a large, Australian, population-based cohort.
Methods: We studied the association between common HLA-DRB1 alleles and genotypes and age of onset as well as three clinical disease severity descriptors: Multiple Sclerosis Severity Score, progression index), and the interval between the first and second attack in 978 patients with relapsing remitting MS and secondary progressive MS. We assessed cognition using the Symbol Digit Modalities Test in 811 patients and brain atrophy using the linear magnetic resonance imaging marker, the intercaudate ratio, in 745 patients.
Results: Carrying DR15 significantly decreased the age of MS onset by 3.2 years in homozygotes and 1.3 years in heterozygotes. Carrying the HLA-DR15, -DR1, -DR3 or -DR4 alone or in combination did not affect clinical disease severity, cognition or cerebral atrophy.
Conclusions: This study confirms that heterogeneity of HLA-DRB1 does not influence disease outcome in relapsing MS patients, with the exception of a younger age of onset in HLA-DR15 carriers.
LincolnMRMontpetitACaderMZ. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet2005; 37: 1108–1112.
2.
SawcerSBanMMaranianM. A high-density screen for linkage in multiple sclerosis. Am J Hum Genet2005; 77: 454–467.
3.
KurtzkeJ. Rating neurological impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology1983; 33: 1444–1452.
4.
RoxburghRHSeamanSRMastermanT. Multiple sclerosis severity score: Using disability and disease duration to rate disease severity. Neurology2005; 64: 1144–1151.
5.
WeatherbySJThomsonWPepperL. HLA-DRB1 and disease outcome in multiple sclerosis. J Neurol2001; 248: 304–310.
6.
HensiekAESawcerSJFeakesR. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry2002; 72: 184–187.
7.
MastermanTLigersAOlssonTAnderssonMOlerupOHillertJ. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol2000; 48: 211–219.
8.
CeliusEGHarboHFEgelandTVartdalFVandvikBSpurkiandA. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci2000; 178: 132–135.
9.
SmestadCBrynedalBJonasdottirG. The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol2007; 14: 835–840.
10.
VillosladaPBarcellosLFRioJ. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol2002; 130: 194–201.
11.
BarcellosLFOksenbergJRBegovichAB. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet2003; 72: 710–716.
12.
BarcellosLFSawcerSRamsayPP. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet2006; 15: 2813–2824.
13.
WuJ-SQiuWCastleyA. Modifying effects of HLA-DRB1 allele interactions on age at onset of multiple sclerosis in Western Australia. Mult Scler2010; 16: 15–20.
14.
StankovichJButzkuevenHMarriottM. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Tissue Antigens2009; 74: 17–21.
15.
DymentDAHerreraBMCaderMZ. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet2005; 14: 2019–2026.
16.
DeLucaGCRamagopalanSVHerreraBM. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A2007; 104: 20896–20901.
17.
OlerupOHillertJFredriksonS. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A1989; 86: 7113–7117.
18.
WeinshenkerBGSantrachPBissonetAS. Major histocompatibility complex class II alleles and the course and outcome of MS: A population-based study. Neurology1998; 51: 742–747.
19.
McDonnellGVMawhinneyHGrahamCAHawkinsSAMiddletonD. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis. J Neurol Sci1999; 165: 77–83.
20.
ButzkuevenHKolbeSJolleyD. Evaluation of linear cerebral atrophy markers in multiple sclerosis. J Clin Neurosci2008; 15: 130–137.
21.
ParmenterBAWeinstock-GuttmanBGargNMunschauerFBenedictRH. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler2007; 13: 52–57.
22.
van der WaltAStankovichJBahloM. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology2009; 73: 1018–1025.
23.
ConfavreuxCVukusicS. Natural history of multiple sclerosis: A unifying concept. Brain2006; 129: 606–616.
24.
de la ConchaEGArroyoRCrusiusJB. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. J Neuroimmunol1997; 80: 172–178.
25.
PoserCMPatyDWScheinbergL. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227–231.
26.
HensiekAESeamanSRBarcellosLF. Familial effects on the clinical course of multiple sclerosis. Neurology2007; 68: 376–383.
27.
RunmarkerBMartinssonTWahlstromJAndersenO. HLA and prognosis in multiple sclerosis. J Neurol1994; 241: 385–390.
28.
Cournu-RebeixIGeninELerayE. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis. Genes Immun2008; 9: 570–574.
29.
GuerreroALLaherranEGutierrezF. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score. Acta Neurol Scand2008; 117: 21–25.
30.
OkudaDTSrinivasanROksenbergJR. Genotype–phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain2009; 132: 250–259.
31.
BarkhofFCalabresiPAMillerDReingoldSC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol2009; 5: 256–266.
32.
De StefanoNMatthewsPFilippiM. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology2003; 60: 1157–1162.
33.
ZivadinovRUxaLZacchiT. HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol2003; 250: 1099–1106.
34.
ZivadinovRUxaLBratinaA. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol2007; 79: 521–535.
35.
FischerJSRudickRACutterGRReingoldSC. The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler1999; 5: 244–250.
36.
BenedictRHBDuquinJAJurgensenS. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler2008; 14: 940–946.
37.
WuJ-SJamesIQiuW. HLA-DRB1 allele hetero- geneity influences multiple sclerosis severity as well as risk in Western Australia. J Neuroimmunol2010; 219: 109–113.
